Efalizumab treatment associated with Candida colitis.
Kitagawa
Kory H
KH
Kalb
Robert E
RE
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D002177:Candidiasis / Q000150:complications* / Q000188:drug therapy; D000077336:Caspofungin; D003092:Colitis / Q000188:drug therapy / Q000382:microbiology*; D003106:Colon / Q000382:microbiology; D054714:Echinocandins / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D055666:Lipopeptides; D008875:Middle Aged; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology*; D011565:Psoriasis / Q000150:complications* / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D054714:Echinocandins; D007166:Immunosuppressive Agents; D055666:Lipopeptides; D000077336:Caspofungin; C472181:efalizumab